Evidence map›Paper›PMID 39866779›Full record

ReviewMaterials today. Bio2025

Brain-targeting drug delivery systems: The state of the art in treatment of glioblastoma.

Bo Sun, Rong Li, Ning Ji, Han Liu, Hongxiang Wang, Chao Chen, Long Bai, Jiacan Su, Juxiang Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Advancements in Drug Delivery Systems in Glioblastoma Therapy.International journal of molecular sciences · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bo SunDepartment of Neurosurgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Rong LiDepartment of Neurosurgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Ning JiInstitute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Han LiuInstitute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Hongxiang WangDepartment of Neurosurgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Chao ChenDepartment of Neurosurgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Long BaiInstitute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Jiacan SuDepartment of Orthopedics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Juxiang ChenDepartment of Neurosurgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most prevalent primary malignant brain tumor, characterized by a high mortality rate and a poor prognosis. The blood-brain barrier (BBB) and the blood-tumor barrier (BTB) present significant obstacles to the efficacy of tumor-targeted pharmacotherapy, thereby impeding the therapeutic potential of numerous candidate drugs. Targeting delivery of adequate doses of drug across the BBB to treat GBM has become a prominent research area in recent years. This emphasis has driven the exploration and evaluation of diverse technologies for GBM pharmacotherapy, with some already undergoing clinical trials. This review provides a thorough overview of recent advancements and challenges in targeted drug delivery for GBM treatment. It specifically emphasizes systemic drug administration strategies to assess their potential and limitations in GBM treatment. Furthermore, this review highlights promising future research directions in the development of intelligent drug delivery systems aimed at overcoming current challenges and enhancing therapeutic efficacy against GBM. These advancements not only support foundational research on targeted drug delivery systems for GBM but also offer methodological approaches for future clinical applications.

Indexed as

Blood brain barrierBlood-tumor barrierBrain targeting drug delivery systemGlioblastomaNanoparticles

Identifiers

PMID39866779
PMCPMC11759563

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.